Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Jiankang Hu"'
Autor:
Xiaoxia Zhu, Jiankang Hu, Dongzhou Liu, Jingyang Li, Huaxiang Wu, Lingyun Sun, Lie Dai, Chunyu Tan, Zhijun Li, Zhengyu Xiao, Xiaomei Li, Yan Yan, Guanshen Dou, Yuzi Sun, Hejian Zou
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 4, Pp 1011-1022 (2024)
Abstract Introduction Ixekizumab, an interleukin 17A (IL-17A) inhibitor, has demonstrated rapid and sustained improvement in the signs and symptoms in patients with active radiographic axial spondyloarthritis (r-axSpA) in global and Chinese populatio
Externí odkaz:
https://doaj.org/article/8631d196342e472686f7d10b244e35b3
Autor:
Hua Ye, Shengyun Liu, Jian Xu, Kexia Chai, Dongyi He, Yongfei Fang, Qibing Xie, Huaxiang Liu, Ying Liu, Bingzhu Hua, Jiankang Hu, Zhiyi Zhang, Mingxuan Zhou, Dongbao Zhao, Yan Li, Zhenyu Jiang, Meimei Wang, Jingyang Li, Zhuoli Zhang, Xiaomei Li, Yang Li, Erwei Sun, Liqi Bi, Wei Wei, Ning Tie, Lan He, Xiangyang Huang, Yan Zhang, Qingchun Huang, Xiaofei Wang, Xiangyuan Liu, Jing Li, Yin Su
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 3, Pp 757-773 (2023)
Abstract Objectives The aim of this work is to verify the non-inferior efficacy and safety of CMAB008 compared with innovator infliximab in rheumatoid arthritis patients combined with methotrexate. Methods We conducted a randomized, double-blinded, p
Externí odkaz:
https://doaj.org/article/36bf076d47534c6eaf652f8daa9e5540
Autor:
Xiaofeng Zeng, Ju Liu, Xiumei Liu, Lijun Wu, Yi Liu, Xiangping Liao, Huaxiang Liu, Jiankang Hu, Xin Lu, Linjie Chen, Jian Xu, Zhenyu Jiang, Fu-ai Lu, Huaxiang Wu, Ying Li, Qingyu Wang, Jun Zhu, the HLX01-RA03 Investigators
Publikováno v:
Arthritis Research & Therapy, Vol 24, Iss 1, Pp 1-11 (2022)
Abstract Background To evaluate the efficacy and safety of HLX01, a rituximab biosimilar, as combination therapy with methotrexate in Chinese patients with active rheumatoid arthritis who had inadequate responses to methotrexate. Methods In this doub
Externí odkaz:
https://doaj.org/article/bf56f5286abe41569c25ccc9aaa15639
Autor:
Xiaofeng Zeng, Cunshan Wang, Yi Liu, Jian Xu, Ju Liu, Zhuoli Zhang, Wenfeng Tan, Shengyun Liu, Wei Lin, Weiguo Wan, Zhenyu Jiang, Zhiyi Zhang, Oluwaseyi Dina, Shixue Liu, XiaoMei Leng, Keith Kanik, Jiankang Hu, Jingyang Li, Levent M. Gunay, Cassandra Kinch
Publikováno v:
RMD Open, Vol 9, Iss 1 (2023)
Objectives Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, were evaluated in a 6-month, double-blind, phase 3 study in Chinese patients with active (polyarthritic) psoriatic arthritis (PsA) and inadequate response to ≥1 conventi
Externí odkaz:
https://doaj.org/article/95e7525994d9450aa6a0ec678516e46f
Autor:
Yue Yang, Jianhua Xu, Jian Xu, Xingfu Li, Jiankang Hu, Xiangpei Li, Xiao Zhang, Dongyi He, Chunde Bao, Zhijun Li, Guochun Wang, Cristiano A. F. Zerbini, Alberto J. Spindler, Carol L. Kannowski, Hanjun Wu, Fei Ji, Lujing Zhan, Mengru Liu, Zhanguo Li
Publikováno v:
Therapeutic Advances in Musculoskeletal Disease, Vol 13 (2021)
Introduction: To assess the effect of baricitinib on patient-reported outcomes (PROs) in patients with moderately to severely active rheumatoid arthritis (RA) who had an inadequate response to methotrexate (MTX). Methods: This was a 52-week, randomiz
Externí odkaz:
https://doaj.org/article/6d86b3f339904dd7b38207ad505040ea
Autor:
Di Wu, Jing Li, Dong Xu, Merrill, Joan T., van Vollenhoven, Ronald F., Yi Liu, Jiankang Hu, Yang Li, Fen Li, Chenghui Huang, Guochun Wang, Xiaomei Li, Jianhong Zhao, Dongbao Zhao, Cibo Huang, Huaxiang Liu, Wei Wei, Guixiu Shi, Fuai Lu, Xiaoxia Zuo
Publikováno v:
Annals of the Rheumatic Diseases; Apr2024, Vol. 83 Issue 4, following p475-487, 22p
Autor:
Hongrui Xu, Guolong Luo, Tianbang Wu, Jiankang Hu, Chao Wang, Xishan Wu, Yan Zhang, Yong Xu, Qiuping Xiang
Publikováno v:
Biochemical and Biophysical Research Communications. 623:17-22
Inhibition of the bromodomain of the CREB (cyclic-AMP response element-binding protein) binding protein (CBP) is a particularly promising new therapeutic approach for cancer. Benzimidazole derivatives CCS1477 and its analogues (8 and 9) are highly po
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ccc52234ff21369ade8871fdc96d30b
https://doi.org/10.1016/j.bbrc.2022.07.021
https://doi.org/10.1016/j.bbrc.2022.07.021
Autor:
Qiuping Xiang, Chao Wang, Tianbang Wu, Cheng Zhang, Qingqing Hu, Guolong Luo, Jiankang Hu, Xiaoxi Zhuang, Lingjiao Zou, Hui Shen, Xishan Wu, Yan Zhang, Xiangqian Kong, Jinsong Liu, Yong Xu
Publikováno v:
Journal of Medicinal Chemistry. 65:785-810
CREB (cyclic-AMP responsive element binding protein) binding protein (CBP) is a potential target for prostate cancer treatment. Herein, we report the structural optimization of a series of 1-(indolizin-3-yl)ethan-1-one compounds as new selective CBP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4d29775f3752b636f481f0de1870730
https://doi.org/10.1021/acs.jmedchem.1c01864
https://doi.org/10.1021/acs.jmedchem.1c01864
Autor:
Xiaomei Leng, Wei Lin, Shixue Liu, Keith Kanik, Cunshan Wang, Weiguo Wan, Zhenyu Jiang, Yi Liu, Shengyun Liu, Zhuoli Zhang, Zhiyi Zhang, Jian Xu, Wenfeng Tan, Jiankang Hu, Jingyang Li, Ju Liu, Levent M. Gunay, Oluwaseyi Dina, Cassandra Kinch, Xiaofeng Zeng
Publikováno v:
RMD Open. 9:e002559
ObjectivesEfficacy and safety of tofacitinib, an oral Janus kinase inhibitor, were evaluated in a 6-month, double-blind, phase 3 study in Chinese patients with active (polyarthritic) psoriatic arthritis (PsA) and inadequate response to ≥1 conventio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::70358f67d2924799b4b9f876cb68e616
https://doi.org/10.1136/rmdopen-2022-002559
https://doi.org/10.1136/rmdopen-2022-002559
Autor:
Xiaofeng, Zeng, Ju, Liu, Xiumei, Liu, Lijun, Wu, Yi, Liu, Xiangping, Liao, Huaxiang, Liu, Jiankang, Hu, Xin, Lu, Linjie, Chen, Jian, Xu, Zhenyu, Jiang, Fu-Ai, Lu, Huaxiang, Wu, Ying, Li, Qingyu, Wang, Jun, Zhu, Jian, Wu
Publikováno v:
Arthritis researchtherapy. 24(1)
To evaluate the efficacy and safety of HLX01, a rituximab biosimilar, as combination therapy with methotrexate in Chinese patients with active rheumatoid arthritis who had inadequate responses to methotrexate.In this double-blind, placebo-controlled
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::018a4b156651353c1cbc68fe5fbc74e1
https://pubmed.ncbi.nlm.nih.gov/35689239
https://pubmed.ncbi.nlm.nih.gov/35689239